About Athos Therapeutics
Athos Therapeutics is a company based in Torrance (United States) founded in 2019. Athos Therapeutics has raised $27.97 million across 2 funding rounds. Athos Therapeutics offers products and services including AI2 Platform. Athos Therapeutics operates in a competitive market with competitors including Moderna, Horizon Therapeutics, Forge Biologics, argenx and Annexon, among others.
- Headquarter Torrance, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Athos Therapeutics Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$27.97 M (USD)
in 2 rounds
-
Latest Funding Round
$7.56 M (USD), Series A
Jan 22, 2024
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Athos Therapeutics
Athos Therapeutics offers a comprehensive portfolio of products and services, including AI2 Platform.
Platform uses AI to identify and develop drugs for autoimmune diseases efficiently.
People of Athos Therapeutics
Unlock access to complete
Leadership Team
7 people
Operations Team
1 people
Research Team
1 people
Senior Team
1 people
Unlock access to complete
Funding Insights of Athos Therapeutics
Athos Therapeutics has successfully raised a total of $27.97M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $7.56 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Athos Therapeutics
Investment portfolio details for Athos Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Athos Therapeutics
Detailed financials for Athos Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Athos Therapeutics Comparisons
Peer comparison for Athos Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Athos Therapeutics
Athos Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Horizon Therapeutics, Forge Biologics, argenx and Annexon, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
|
| Locked | Locked | Locked |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Therapeutics for autoimmune diseases are developed by the company.
|
Detailed competitors of Athos Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Athos Therapeutics
Complete news archive for Athos Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Athos Therapeutics
Athos Therapeutics was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Athos Therapeutics is headquartered in Torrance, United States. It is registered at Torrance, California, United States.
Dimitrios Iliopoulos is the current CEO of Athos Therapeutics.
Athos Therapeutics is a funded company, having raised a total of $27.97M across 2 funding rounds to date.
Athos Therapeutics was founded in 2019 and is based in Torrance, United States. Operations focus on the biotechnology sector, where machine learning algorithms are utilized to identify drug and gene targets for autoimmune conditions. A computational process is employed to ensure targets are novel and safe for individual patients. The pipeline features ATH-63, ATH-105, and ATH-120, targeted at ulcerative colitis and Crohns disease.
Athos Therapeutics's top competitors include Moderna, argenx and Forge Biologics.
Athos Therapeutics offers AI2 Platform.